PharmaShots | Incisive News in 3 Shots

Subscribe Now

merck & co.

Merck & Co. Acquires Harpoon Therapeutics for ~$680M

Merck & Co. Acquires Harpoon Therapeutics for ~$680M

January 10, 2024

Merck & Co. Receives the US FDA’s Approval for Welireg (belzutifan) to Treat Advanced Renal Cell Carcinoma (RCC)

Merck & Co. Receives the US FDA’s Approval for Welireg (belzutifan) to Treat Advanced Renal Cell Carcinoma (RCC)

December 15, 2023

Merck’s Keytruda with Gemcitabine and Cisplatin Received the US FDA’s Approval to Treat Biliary Tract Cancer

Merck’s Keytruda with Gemcitabine and Cisplatin Received the US FDA’s Approval to Treat Biliary Tract Cancer

November 2, 2023

Merck’s P-III Trial Assessing Keytruda Met its Secondary Endpoint in Renal Cell Carcinoma (RCC) Patients

Merck’s P-III Trial Assessing Keytruda Met its Secondary Endpoint in Renal Cell Carcinoma (RCC) Patients

November 2, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us